{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:51:15Z","timestamp":1790941875393,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>On-treatment platelet reactivity in clopidogrel-treated patients can be measured with several platelet function tests (PFTs). However, the agreement between different PFTs is only slight to moderate. Polymorphisms of the CYP2C19 gene have an impact on the metabolization of clopidogrel and, thereby, have an impact on on-treatment platelet reactivity. The aim of the current study is to evaluate the differential effects of the CYP2C19 genotype on three different PFTs. Methods: From a prospective cohort study, we included patients treated with clopidogrel following percutaneous coronary intervention (PCI). One month after PCI, we simultaneously performed three different PFTs; light transmission aggregometry (LTA), VerifyNow P2Y12, and Multiplate. In whole EDTA blood, genotyping of the CYP2C19 polymorphisms was performed. Results: We included 308 patients treated with clopidogrel in combination with aspirin (69.5%) and\/or anticoagulants (33.8%) and, based on CYP2C19 genotyping, classified them as either extensive (36.4%), rapid (34.7%), intermediate (26.0%), or poor metabolizers (2.9%). On-treatment platelet reactivity as measured by LTA and VerifyNow is significantly affected by CYP2C19 metabolizer status (p &lt; 0.01); as metabolizer status changes from rapid, via extensive and intermediate, to poor, the mean platelet reactivity increases accordingly (p &lt; 0.01). On the contrary, for Multiplate, no such ordering of metabolizer groups was found (p = 0.10). Conclusions: For VerifyNow and LTA, the on-treatment platelet reactivity in clopidogrel-treated patients correlates well with the underlying CYP2C19 polymorphism. For Multiplate, no major effect of genetic background could be shown, and effects of other (patient-related) variables prevail. Thus, besides differences in test principles and the influence of patient-related factors, the disagreement between PFTs is partly explained by differential effects of the CYP2C19 genotype.<\/jats:p>","DOI":"10.3390\/jcm10173992","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T13:09:25Z","timestamp":1630933765000},"page":"3992","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients"],"prefix":"10.3390","volume":"10","author":[{"given":"Renske H.","family":"Olie","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"},{"name":"Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands"},{"name":"Thrombosis Expertise Center, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle R. K.","family":"Hensgens","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"},{"name":"Central Diagnostic Laboratory, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petal A. H. M.","family":"Wijnen","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca T. A.","family":"de Greef","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minka J. A.","family":"Vries","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-2583","authenticated-orcid":false,"given":"Paola E. J.","family":"van der Meijden","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands"},{"name":"Thrombosis Expertise Center, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"},{"name":"Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-4463","authenticated-orcid":false,"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"},{"name":"Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands"},{"name":"Thrombosis Expertise Center, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Bekers","sequence":"additional","affiliation":[{"name":"Central Diagnostic Laboratory, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne M. C.","family":"Henskens","sequence":"additional","affiliation":[{"name":"Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands"},{"name":"Central Diagnostic Laboratory, Maastricht University Medical Center+ (MUMC+), 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_2","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamainternmed.2018.0783","article-title":"Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008\u20132016","volume":"178","author":"Dayoub","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: Very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1538-7836.2011.04570.x","article-title":"The gain-of-function variant allele CYP2C19*17: A double-edged sword between thrombosis and bleeding in clopidogrel-treated patients","volume":"10","author":"Li","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1055\/s-0038-1667337","article-title":"Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy","volume":"118","author":"Gross","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ahj.2010.06.039","article-title":"Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events","volume":"160","author":"Tiroch","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cpt.2039","article-title":"Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention","volume":"109","author":"Lee","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jth.12342","article-title":"The CYP2C19*17 variant is not independently associated with clopidogrel response","volume":"11","author":"Lewis","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvw026","article-title":"Determinants of agreement between proposed therapeutic windows of platelet function tests in vulnerable patients","volume":"3","author":"Vries","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1093\/eurheartj\/ehn419","article-title":"Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients","volume":"29","author":"Lordkipanidze","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1160\/TH08-09-0577","article-title":"Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation","volume":"101","author":"Gremmel","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1538-7836.2007.02656.x","article-title":"Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients","volume":"5","author":"Paniccia","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_28","first-page":"287","article-title":"Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients","volume":"104","author":"Paniccia","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcin.2020.01.219","article-title":"Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study","volume":"13","author":"Hulot","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Olie, R.H., Van der Meijden, P.E.J., Vries, M.J.A., Veenstra, L., van\u2019t Hof, A.W.J., Ten Berg, J.M., Henskens, Y.M.C., and Ten Cate, H. (2021). Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events. Neth. Heart J.","DOI":"10.1007\/s12471-021-01606-2"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cpt.762","article-title":"Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group","volume":"103","author":"Bank","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.thromres.2011.05.008","article-title":"The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent","volume":"128","author":"Gremmel","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0049-3848(97)00114-X","article-title":"Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin","volume":"87","author":"Wallen","year":"1997","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/09537100802317918","article-title":"The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence","volume":"19","author":"Harmsze","year":"2008","journal-title":"Platelets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/09537104.2020.1754378","article-title":"The Influence of Prostaglandin E1 and Use of Inhibitor Percentage on the Correlation between the Multiplate and VerifyNow in Patients on Dual Antiplatelet Therapy","volume":"32","author":"Hulshof","year":"2020","journal-title":"Platelets"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FPC.0b013e32834ff6e3","article-title":"The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting","volume":"22","author":"Harmsze","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1538-7836.2009.03500.x","article-title":"The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome","volume":"7","author":"Frere","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijcard.2011.10.010","article-title":"Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests","volume":"166","author":"Gremmel","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Collet, J.P., Thiele, H., Barbato, E., Barthelemy, O., Bauersachs, J., Bhatt, D.L., Dendale, P., Dorobantu, M., Edvardsen, T., and Folliguet, T. (2020). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J.","DOI":"10.15829\/1560-4071-2021-4418"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite Investigation of Outcomes with Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2018.03.021","article-title":"Pharmacogenomic Testing to Select Antiplatelet Therapy","volume":"71","author":"Price","year":"2018","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3992\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:55:58Z","timestamp":1760165758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/17\/3992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":49,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10173992"],"URL":"https:\/\/doi.org\/10.3390\/jcm10173992","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}